<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/glp1-tam-rehber.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/glp1-tam-rehber.html">
<meta http-equiv="Content-Language" content="tr">
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script src="/scripts/https-redirect.js"></script>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro | UzunYaÅŸa</title>
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
 <meta name="description" content="Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? TÃ¼m klinik veriler ve TÃ¼rkiye'deki eriÅŸim bilgileri.">
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Playfair+Display:wght@500;600&display=swap" rel="stylesheet">
 <link rel="stylesheet" href="../../styles/main.css">
 <link rel="stylesheet" href="../../styles/animations.css">
 <style>
 article { max-width: 800px; margin: 0 auto; padding: 7rem 2rem 4rem; }
 .post-meta-top { display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 1.5rem; }
 .post-category { display: inline-block; background: #EC4899; color: white; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; }
 .reading-time { color: var(--text-gray); font-size: 0.9rem; }
 h1 { font-family: 'Playfair Display', serif; font-size: 2.5rem; font-weight: 600; line-height: 1.2; margin-bottom: 1rem; color: var(--text); }
 .subtitle { font-size: 1.15rem; color: var(--text-gray); margin-bottom: 2rem; line-height: 1.6; }
 .featured-image { width: 100%; height: 300px; background: linear-gradient(135deg, rgba(236,72,153,0.8), rgba(219,39,119,0.8)), url("https://images.unsplash.com/photo-1631549916768-4119b2e5f926?w=800&q=80") center/cover; border-radius: 16px; margin-bottom: 2rem; display: flex; align-items: center; justify-content: center; }
 .featured-image span { font-size: 4rem; }
 .toc { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.5rem; margin-bottom: 2rem; }
 .toc h3 { font-size: 1rem; font-weight: 600; margin-bottom: 1rem; color: var(--primary); }
 .toc ul { list-style: none; }
 .toc li { margin-bottom: 0.5rem; }
 .toc a { color: var(--text-gray); text-decoration: none; font-size: 0.9rem; }
 .toc a:hover { color: var(--primary); }
 .content p { margin-bottom: 1.5rem; font-size: 1.05rem; }
 .content h2 { font-size: 1.6rem; font-weight: 700; margin: 3rem 0 1rem; color: var(--primary); padding-top: 1rem; border-top: 1px solid #e5e7eb; }
 .content h3 { font-size: 1.25rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text); }
 .content ul, .content ol { margin: 1.5rem 0; padding-left: 1.5rem; }
 .content li { margin-bottom: 0.5rem; font-size: 1.02rem; }
 .content strong { color: var(--text); }
 .info-box { background: #eff6ff; border-left: 4px solid #3b82f6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .warning-box { background: #fef3c7; border-left: 4px solid #f59e0b; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .success-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .quote-box { background: #faf5ff; border-left: 4px solid #8b5cf6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; font-style: italic; }
 .stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 1rem; margin: 2rem 0; }
 .stat-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.25rem; text-align: center; }
 .stat-card .number { font-size: 1.75rem; font-weight: 800; color: var(--primary); }
 .stat-card .label { font-size: 0.8rem; color: var(--text-gray); margin-top: 0.25rem; }
 table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; font-size: 0.95rem; }
 th, td { padding: 0.75rem; text-align: left; border-bottom: 1px solid #e5e7eb; }
 th { background: #f8fafc; font-weight: 600; color: var(--primary); }
 .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
 .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
 .author-box { display: flex; align-items: center; gap: 1rem; padding: 1.5rem; background: white; border-radius: 12px; border: 1px solid #e5e7eb; margin: 2rem 0; }
 .author-avatar { width: 60px; height: 60px; background: var(--primary); border-radius: 50%; display: flex; align-items: center; justify-content: center; color: white; font-weight: 700; }
 .author-info h4 { font-weight: 600; margin-bottom: 0.25rem; }
 .author-info p { font-size: 0.85rem; color: var(--text-gray); }
 
 @media (max-width: 640px) { h1 { font-size: 1.8rem; } article { padding: 6rem 1rem 3rem; } .stat-grid { grid-template-columns: repeat(2, 1fr); } }
 
 .key-stat-box { background: linear-gradient(135deg, #f0fdfa, #ecfdf5); border-left: 5px solid #0D7377; border-radius: 0 16px 16px 0; padding: 1.5rem 2rem; margin: 2rem 0; display: flex; align-items: center; gap: 1.25rem; }
 .key-stat-box .ks-number { font-size: 2.5rem; font-weight: 800; color: #0D7377; line-height: 1; white-space: nowrap; }
 .key-stat-box .ks-context { font-size: 0.95rem; color: #195157; line-height: 1.5; }
 .key-stat-box.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
 .key-stat-box.accent .ks-number { color: #E8963E; }
 @media (max-width: 640px) { .key-stat-box .ks-number { font-size: 1.8rem; } .key-stat-box { flex-direction: column; text-align: center; } }
 </style>

    <meta property="og:title" content="GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro">
    <meta property="og:description" content="Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? TÃ¼m klinik veriler ve TÃ¼rkiye'deki eriÅŸim bilgileri.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/glp1-tam-rehber.html">
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="og:locale" content="tr_TR">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro">
    <meta name="twitter:description" content="Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? TÃ¼m klinik veriler ve TÃ¼rkiye'deki eriÅŸim bilgileri.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/glp1-tam-rehber.html">
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro | UzunYaÅŸa",
  "description": "Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? TÃ¼m klinik veriler ve TÃ¼rkiye",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-01",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/glp1-tam-rehber.html",
  "image": "https://uzunyasa.com/images/og-default.png"
}
</script>
</head>
<body>
 <header class="header">
 <div class="header-inner">
 <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
 <a href="../blog.html" class="back-link">â† Blog</a>
 </div>
 </header>

 <article>
 <div class="post-meta-top">
 <span class="post-category"> GLP-1 Ä°laÃ§larÄ±</span>
 <span class="reading-time">â± 22 dk okuma â€¢ Åubat 2026</span>
 </div>
 
 <h1>GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro</h1>
 <p class="subtitle">Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? BÄ±rakÄ±nca ne olur? TÃ¼m klinik veriler, gerÃ§ekÃ§i beklentiler ve TÃ¼rkiye'deki eriÅŸim bilgileri.</p>

 <div class="featured-image"></div>

 <div class="toc">
 <h3> Ä°Ã§indekiler</h3>
 <ul>
 <li><a href="#nedir">GLP-1 Ä°laÃ§larÄ± Nedir?</a></li>
 <li><a href="#nasil">NasÄ±l Ã‡alÄ±ÅŸÄ±rlar?</a></li>
 <li><a href="#ilaclar">Piyasadaki Ä°laÃ§lar</a></li>
 <li><a href="#kilo">Kilo KaybÄ± Verileri</a></li>
 <li><a href="#faydalar">DiÄŸer SaÄŸlÄ±k FaydalarÄ±</a></li>
 <li><a href="#yan-etkiler">Yan Etkiler</a></li>
 <li><a href="#birakinca">BÄ±rakÄ±nca Ne Olur?</a></li>
 <li><a href="#turkiye">TÃ¼rkiye'de EriÅŸim</a></li>
 <li><a href="#kimler">Kimler Kullanabilir?</a></li>
 <li><a href="#yasam-tarzi">YaÅŸam TarzÄ± ile Kombinasyon</a></li>
 <li><a href="#takip">Tedavi SÃ¼reci ve Takip</a></li>
 </ul>
 </div>

 <div class="content">
 <div class="key-stat-box"><span class="ks-number">15-22%</span><span class="ks-context">GLP-1 ilaÃ§larÄ±yla ortalama kilo kaybÄ± aralÄ±ÄŸÄ± â€” Semaglutid 2.4mg: ~%15 (STEP-1) ğŸŸ¢, Tirzepatid 15mg: ~%21 (SURMOUNT-1) ğŸŸ¢</span></div>
 <h2 id="nedir">GLP-1 Ä°laÃ§larÄ± Nedir?</h2>
 <p>GLP-1 reseptÃ¶r agonistleri, son yÄ±llarÄ±n en Ã¶nemli ilaÃ§ sÄ±nÄ±flarÄ±ndan biri haline geldi. BaÅŸlangÄ±Ã§ta tip 2 diyabet tedavisi iÃ§in geliÅŸtirilen bu ilaÃ§lar, obezite tedavisinde Ã¶nemli bir dÃ¶nÃ¼m noktasÄ± oldu.</p>
 
 <p>"GLP-1" kÄ±saltmasÄ±, <strong>Glucagon-Like Peptide-1</strong> anlamÄ±na gelir â€” baÄŸÄ±rsaklarÄ±mÄ±zÄ±n yemek yediÄŸimizde doÄŸal olarak salgÄ±ladÄ±ÄŸÄ± bir hormon.</p>

 


 <div class="stat-grid">
 <div class="stat-card"><div class="number">25M+</div><div class="label">DÃ¼nya genelinde hasta</div></div>
 <div class="stat-card"><div class="number">%15-22</div><div class="label">Ortalama kilo kaybÄ±</div></div>
 <div class="stat-card"><div class="number">%20</div><div class="label">Kalp hastalÄ±ÄŸÄ± risk azalmasÄ±</div></div>
 </div>

 <h2 id="nasil">NasÄ±l Ã‡alÄ±ÅŸÄ±rlar?</h2>
 
 <h3>1. Beyin Ãœzerindeki Etki</h3>
 <p>Ä°laÃ§lar, beyindeki tokluk merkezini (hipotalamus) uyararak aÃ§lÄ±k hissini belirgin ÅŸekilde azaltÄ±r. Hastalar genellikle "yemek dÃ¼ÅŸÃ¼nmÃ¼yorum artÄ±k" ÅŸeklinde tanÄ±mlar.</p>

 <h3>2. Mide Ãœzerindeki Etki</h3>
 <p>Midenin boÅŸalma hÄ±zÄ±nÄ± yavaÅŸlatÄ±r. Yemekten sonra daha uzun sÃ¼re tok hissedersiniz.</p>

 <h3>3. Pankreas Ãœzerindeki Etki</h3>
 <p>Kan ÅŸekeri yÃ¼kseldiÄŸinde insÃ¼lin salÄ±nÄ±mÄ±nÄ± artÄ±rÄ±r, dÃ¼ÅŸÃ¼k olduÄŸunda artÄ±rmaz. Bu "akÄ±llÄ±" mekanizma hipoglisemi riskini minimuma indirir.</p>

 <h2 id="ilaclar">Piyasadaki GLP-1 Ä°laÃ§larÄ±</h2>

 <h3>Semaglutid Ailesi (Novo Nordisk)</h3>
 <table>
 <tr><th>Ä°laÃ§</th><th>Endikasyon</th><th>Doz</th><th>Uygulama</th></tr>
 <tr><td><strong>Ozempic</strong></td><td>Tip 2 diyabet</td><td>0.25-2 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
 <tr><td><strong>Wegovy</strong></td><td>Obezite</td><td>2.4 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
 <tr><td><strong>Rybelsus</strong></td><td>Tip 2 diyabet</td><td>3-14 mg/gÃ¼n</td><td>GÃ¼nlÃ¼k oral tablet</td></tr>
 </table>

 <h3>Tirzepatid Ailesi (Eli Lilly)</h3>
 <table>
 <tr><th>Ä°laÃ§</th><th>Endikasyon</th><th>Doz</th><th>Uygulama</th></tr>
 <tr><td><strong>Mounjaro</strong></td><td>Tip 2 diyabet</td><td>5-15 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
 <tr><td><strong>Zepbound</strong></td><td>Obezite</td><td>5-15 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
 </table>

 <h3>TÃ¼rkiye'de Mevcut DiÄŸer GLP-1 Ä°laÃ§larÄ±</h3>
 <table>
 <tr><th>Ä°laÃ§</th><th>Etken Madde</th><th>Endikasyon</th><th>Uygulama</th></tr>
 <tr><td><strong>Victoza</strong></td><td>Liraglutid</td><td>Tip 2 diyabet</td><td>GÃ¼nlÃ¼k enjeksiyon</td></tr>
 <tr><td><strong>Saxenda</strong></td><td>Liraglutid 3mg</td><td>Obezite</td><td>GÃ¼nlÃ¼k enjeksiyon</td></tr>
 <tr><td><strong>Trulicity</strong></td><td>Dulaglutid</td><td>Tip 2 diyabet</td><td>HaftalÄ±k enjeksiyon</td></tr>
 <tr><td><strong>Bydureon</strong></td><td>Exenatide</td><td>Tip 2 diyabet</td><td>HaftalÄ±k enjeksiyon</td></tr>
 </table>

 <div class="info-box">
 <strong> Ã–nemli fark:</strong> Tirzepatid, "Ã§ift agonist" olarak hem GLP-1 hem de GIP reseptÃ¶rlerini aktive eder. Bu nedenle semaglutidden daha yÃ¼ksek kilo kaybÄ± saÄŸlar.
 </div>

 <h2 id="kilo">Kilo KaybÄ±: Klinik Ã‡alÄ±ÅŸma Verileri</h2>

 <h3>Semaglutid (Wegovy): STEP Ã‡alÄ±ÅŸmalarÄ±</h3>
 <p><strong>STEP 1</strong> (1.961 katÄ±lÄ±mcÄ±, 68 hafta):</p>
 <ul>
 <li>Semaglutid grubu: <strong>%14.9</strong> kilo kaybÄ±</li>
 <li>â‰¥%10 kilo kaybÄ±: <strong>%69.1</strong> hastada</li>
 <li>â‰¥%15 kilo kaybÄ±: <strong>%50.5</strong> hastada</li>
 </ul>

 <h3>Tirzepatid (Zepbound): SURMOUNT Ã‡alÄ±ÅŸmalarÄ±</h3>
 <p><strong>SURMOUNT-1</strong> (2.539 katÄ±lÄ±mcÄ±, 72 hafta):</p>
 <ul>
 <li>15 mg doz: <strong>%20.9</strong> kilo kaybÄ±</li>
 <li><strong>%57</strong> hastalar â‰¥%20 kilo kaybetti</li>
 <li><strong>%36</strong> hastalar â‰¥%25 kilo kaybetti</li>
 </ul>

 <div class="success-box">
 <strong>Kafa Kafaya KarÅŸÄ±laÅŸtÄ±rma (SURMOUNT-5):</strong><br>
 Tirzepatid: <strong>%20.2</strong> kilo kaybÄ±<br>
 Semaglutid: %13.7 kilo kaybÄ±<br>
 Fark: 6.5 puan tirzepatid lehine
 </div>

 <h2 id="faydalar">Kilo KaybÄ±nÄ±n Ã–tesinde: SaÄŸlÄ±k FaydalarÄ±</h2>

 <h3>Kalp-Damar SaÄŸlÄ±ÄŸÄ± (SELECT Ã‡alÄ±ÅŸmasÄ±) ğŸŸ¢</h3>
 <ul>
 <li>MajÃ¶r kalp olaylarÄ±nÄ± (MACE) <strong>%20 azalttÄ±</strong> (HR 0.80, %95 GA 0.72-0.90, p&lt;0.001) â€” istatistiksel olarak anlamlÄ±</li>
 <li>TÃ¼m nedenlerden Ã¶lÃ¼mde %19 sayÄ±sal azalma gÃ¶zlendi ancak <strong>istatistiksel anlamlÄ±lÄ±ÄŸa ulaÅŸmadÄ±</strong> (HR 0.81, p=0.08)</li>
 </ul>

 <h3>BÃ¶brek KorumasÄ± (FLOW Ã‡alÄ±ÅŸmasÄ±) ğŸŸ¢</h3>
 <ul>
 <li>MajÃ¶r bÃ¶brek olaylarÄ±nda <strong>%24 azalma</strong> (HR 0.76) â€” Ã§alÄ±ÅŸma etkinlik nedeniyle erken durduruldu</li>
 </ul>

 <h3>KaraciÄŸer YaÄŸlanmasÄ± (ESSENCE) ğŸŸ¢</h3>
 <ul>
 <li>Semaglutide 2.4mg ile <strong>%37-43</strong> hastada MASH Ã§Ã¶zÃ¼mÃ¼ (doza baÄŸlÄ±)</li>
 </ul>

 <h2 id="yan-etkiler">Yan Etkiler ve Riskler</h2>

 <h3>En YaygÄ±n: Gastrointestinal</h3>
 <table>
 <tr><th>Yan Etki</th><th>Semaglutid</th><th>Plasebo</th></tr>
 <tr><td>BulantÄ±</td><td><strong>%43.9</strong></td><td>%16.1</td></tr>
 <tr><td>Ä°shal</td><td><strong>%29.7</strong></td><td>%15.9</td></tr>
 <tr><td>Kusma</td><td><strong>%24.5</strong></td><td>%6.3</td></tr>
 <tr><td>KabÄ±zlÄ±k</td><td><strong>%24.2</strong></td><td>%10.1</td></tr>
 </table>

 <div class="info-box">
 <strong> Ã–nemli:</strong> Bu yan etkilerin %99.5'i ciddi deÄŸildi ve %98.1'i hafif-orta ÅŸiddetteydi. Sadece %4.3 hasta tedaviyi bÄ±raktÄ±.
 </div>

 <h3>Kas KaybÄ±</h3>
 <p>Kaybedilen kilonun yaklaÅŸÄ±k %25-40'Ä± yaÄŸsÄ±z kÃ¼tle olabilir (STEP-1: %39, SURMOUNT-1: %33). <strong>Ã–nlem:</strong></p>
 <ul>
 <li>Haftada 2-3 gÃ¼n direnÃ§ egzersizi (zorunlu)</li>
 <li>GÃ¼nde 1.2-1.6 g/kg protein (ESPEN kÄ±lavuzu)</li>
 </ul>

 <h2 id="birakinca">Kritik Soru: BÄ±rakÄ±nca Ne Olur?</h2>

 <div class="warning-box">
 <strong> Ã–nemli UyarÄ±:</strong> Ä°laÃ§ bÄ±rakÄ±ldÄ±ÄŸÄ±nda kilo geri geliyor. STEP 1 uzantÄ±sÄ±nda, bÄ±rakÄ±ldÄ±ktan 1 yÄ±l sonra kaybedilen kilonun <strong>%67'si</strong> (yaklaÅŸÄ±k 2/3) geri alÄ±ndÄ±.
 </div>

 <p><strong>Geri AlÄ±mÄ± Azaltma Stratejileri:</strong></p>
 <ul>
 <li>YapÄ±landÄ±rÄ±lmÄ±ÅŸ egzersiz programÄ±</li>
 <li>YÃ¼ksek protein diyeti</li>
 <li>Kademeli doz azaltma</li>
 <li>Oral alternatiflere geÃ§iÅŸ</li>
 </ul>

 <div class="quote-box">
 <strong> Biliyor Muydunuz?</strong><br>
 GLP-1 ilaÃ§larÄ±, hipertansiyon ilaÃ§larÄ± gibi dÃ¼ÅŸÃ¼nÃ¼lmeli. Tansiyon ilacÄ± bÄ±rakÄ±ldÄ±ÄŸÄ±nda tansiyon nasÄ±l yÃ¼kselirse, GLP-1 bÄ±rakÄ±ldÄ±ÄŸÄ±nda kilo da geri gelir. Bu, ilacÄ±n "baÅŸarÄ±sÄ±zlÄ±ÄŸÄ±" deÄŸil, kronik bir hastalÄ±ÄŸÄ±n doÄŸasÄ±.
 </div>

 <h2 id="turkiye">TÃ¼rkiye'de EriÅŸim ve Maliyet</h2>

 <table>
 <tr><th>Ä°laÃ§</th><th>TÃ¼rkiye Durumu</th><th>Tahmini AylÄ±k Maliyet</th></tr>
 <tr><td>Ozempic</td><td>ReÃ§eteli, SGK sÄ±nÄ±rlÄ±</td><td>3.500-5.000 TL</td></tr>
 <tr><td>Wegovy</td><td>HenÃ¼z resmi lansman yok</td><td>-</td></tr>
 <tr><td>Mounjaro</td><td>TÃ¼rkiye'de yok</td><td>-</td></tr>
 </table>

 <p><strong>Not:</strong> Semaglutid patentleri 2030'larÄ±n baÅŸÄ±na kadar sÃ¼rmektedir; jenerikler kÄ±sa vadede beklenmemektedir. Ancak oral kÃ¼Ã§Ã¼k molekÃ¼l GLP-1'ler (orforglipron gibi) onay aldÄ±ÄŸÄ±nda maliyetlerin dÃ¼ÅŸmesi beklenmektedir.</p>

 <h2 id="kimler">Kimler Kullanabilir?</h2>

 <h3>Uygun Hastalar</h3>
 <ul>
 <li>BMI â‰¥30 kg/mÂ² (obez bireyler)</li>
 <li>BMI â‰¥27 kg/mÂ² + komorbidite (diyabet, hipertansiyon, dislipidemi vb.)</li>
 <li>Tip 2 diyabet tedavisinde kan ÅŸekeri kontrolÃ¼ saÄŸlanamayan hastalar</li>
 <li>KardiyovaskÃ¼ler risk faktÃ¶rleri bulunan kiÅŸiler</li>
 <li>Diyet ve egzersizle yeterli sonuÃ§ alamayanlar</li>
 </ul>

 <h3>KullanÄ±lmamasÄ± Gereken Durumlar</h3>
 <ul>
 <li>Tip 1 diyabet</li>
 <li>MedÃ¼ller tiroid kanseri Ã¶ykÃ¼sÃ¼ veya ailede MTC Ã¶ykÃ¼sÃ¼</li>
 <li>Multiple endokrin neoplazi sendromu tip 2 (MEN2)</li>
 <li>Hamilelik ve emzirme dÃ¶nemleri</li>
 <li>AÄŸÄ±r bÃ¶brek yetmezliÄŸi (eGFR &lt;15 mL/dk)</li>
 <li>Akut pankreatit Ã¶ykÃ¼sÃ¼</li>
 </ul>

 <h2 id="yasam-tarzi">YaÅŸam TarzÄ± ile Kombinasyon</h2>

 <p>GLP-1 ilaÃ§larÄ± tek baÅŸÄ±na Ã§Ã¶zÃ¼m deÄŸildir. En iyi sonuÃ§lar, kapsamlÄ± bir yaÅŸam tarzÄ± programÄ±yla birlikte elde edilir:</p>

 <h3>Beslenme Ã–nerileri</h3>
 <ul>
 <li><strong>Protein aÄŸÄ±rlÄ±klÄ± beslenme:</strong> GÃ¼nde 1.2-1.6 g/kg protein (kas kaybÄ±nÄ± Ã¶nlemek iÃ§in kritik)</li>
 <li>Lifli gÄ±dalarÄ± tercih etme (sebze, baklagiller, tam tahÄ±llar)</li>
 <li>Ä°ÅŸlenmiÅŸ gÄ±dalardan ve ÅŸekerli iÃ§eceklerden kaÃ§Ä±nma</li>
 <li>KÃ¼Ã§Ã¼k porsiyonlar halinde, dÃ¼zenli Ã¶ÄŸÃ¼n saatlerinde beslenme</li>
 </ul>

 <h3>Egzersiz ProgramÄ±</h3>
 <ul>
 <li>Haftada en az 150 dakika orta yoÄŸunlukta aerobik aktivite</li>
 <li><strong>DirenÃ§/kuvvet egzersizleri haftada 2-3 kez (kas korumasÄ± iÃ§in zorunlu)</strong></li>
 <li>GÃ¼nlÃ¼k adÄ±m sayÄ±sÄ±nÄ± artÄ±rma (8.000-10.000 adÄ±m hedefi)</li>
 </ul>

 <h2 id="takip">Tedavi SÃ¼reci ve Takip</h2>

 <h3>Ä°lk 3 Ay</h3>
 <ul>
 <li>AylÄ±k doktor kontrolÃ¼</li>
 <li>Yan etki takibi ve doz ayarlamasÄ±</li>
 <li>Kilo, bel Ã§evresi ve kan basÄ±ncÄ± Ã¶lÃ§Ã¼mÃ¼</li>
 <li>Kan testleri (HbA1c, bÃ¶brek fonksiyonlarÄ±, karaciÄŸer enzimleri)</li>
 </ul>

 <h3>Uzun DÃ¶nem Takip</h3>
 <ul>
 <li>3 ayda bir kontrol muayenesi</li>
 <li>YÄ±lda bir kez kapsamlÄ± check-up</li>
 <li>KardiyovaskÃ¼ler risk deÄŸerlendirmesi</li>
 <li>Kas kÃ¼tlesi ve vÃ¼cut kompozisyonu takibi</li>
 </ul>

 <h2>SonuÃ§: Sizin Ä°Ã§in DoÄŸru mu?</h2>

 <p>GLP-1 ilaÃ§larÄ±, bilimsel olarak kanÄ±tlanmÄ±ÅŸ etkili kilo verme ve metabolik saÄŸlÄ±k araÃ§larÄ±dÄ±r. Ancak bu ilaÃ§lar tek baÅŸÄ±na Ã§Ã¶zÃ¼m deÄŸil, kapsamlÄ± bir yaÅŸam tarzÄ± deÄŸiÅŸikliÄŸi programÄ±nÄ±n parÃ§asÄ± olmalÄ±dÄ±r.</p>

 <p><strong>Ã–nemli:</strong> GLP-1 ilaÃ§larÄ± reÃ§eteli ilaÃ§lardÄ±r ve mutlaka bir endokrinoloji uzmanÄ±nÄ±n deÄŸerlendirmesi ve takibi altÄ±nda kullanÄ±lmalÄ±dÄ±r.</p>

 <h2>Kaynaklar</h2>
 <ol style="font-size:0.9rem;color:#6b7280;">
 <li>Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). <em>N Engl J Med.</em> 2021;384:989-1002.</li>
 <li>Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). <em>N Engl J Med.</em> 2022;387:205-216.</li>
 <li>Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity (SELECT). <em>N Engl J Med.</em> 2023;389:2221-2232.</li>
 <li>Perkovic V et al. Semaglutide and kidney outcomes in type 2 diabetes (FLOW). <em>N Engl J Med.</em> 2024;391:109-121.</li>
 <li>Aronne LJ et al. Tirzepatide vs semaglutide for obesity (SURMOUNT-5). <em>N Engl J Med.</em> 2025;393:26-36.</li>
 <li>Rubino DM et al. Effect of continued vs withdrawn semaglutide (STEP 4). <em>JAMA.</em> 2021;325:1414-1425.</li>
 <li>Novo Nordisk. Semaglutide in MASH (ESSENCE). Phase 3 results, 2024.</li>
 <li>ESPEN Guidelines on Clinical Nutrition in Obesity. <em>Clin Nutr.</em> 2022.</li>
 </ol>

 <div style="background:linear-gradient(135deg,#f0fdfa,#ecfdf5);border:2px solid #0D7377;border-radius:16px;padding:2rem;text-align:center;margin:2rem 0;">
  <p style="font-size:1.1rem;font-weight:700;color:#0D7377;margin-bottom:0.5rem;">ğŸ’Š GLP-1 Size Uygun mu?</p>
  <p style="font-size:0.95rem;color:#374151;margin-bottom:1rem;">Klinik kÄ±lavuzlara dayalÄ± Ã¼cretsiz Ã¶n deÄŸerlendirme testini yapÄ±n.</p>
  <a href="../araclar/glp1-uygunluk-testi.html" style="display:inline-block;background:#0D7377;color:white;padding:0.75rem 2rem;border-radius:10px;text-decoration:none;font-weight:600;">Teste BaÅŸla â†’</a>
 </div>

 
 



 



 <!-- BLOG SUMMARY - Auto-generated -->
 <div class="blog-summary" style="margin-top: 4rem; padding-top: 2rem; border-top: 2px solid #e5e7eb;">
 <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 1.5rem;">
 <div style="width: 4px; height: 32px; background: linear-gradient(to bottom, #195157, #2a7d83); border-radius: 2px;"></div>
 <h2 style="margin: 0; font-family: 'Playfair Display', serif; font-size: 1.75rem; color: #195157;">Ã–zet</h2>
 </div>
 
 <blockquote style="margin: 0 0 1.5rem 0; padding: 1.5rem 2rem; background: linear-gradient(135deg, #f0fdf4 0%, #ecfeff 100%); border-left: 4px solid #195157; border-radius: 0 12px 12px 0; font-size: 1.1rem; line-height: 1.8; color: #374151; font-style: italic;">
 Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? TÃ¼m klinik veriler ve TÃ¼rkiye'deki eriÅŸim bilgileri.
 </blockquote>
 
 <div style="margin-bottom: 1.5rem;">
 <p style="font-weight: 600; color: #195157; margin-bottom: 0.75rem; font-size: 0.95rem;"> Bu rehberde:</p>
 <ul style="list-style: none; padding: 0; margin: 0; display: grid; gap: 0.5rem;">
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> GLP-1 Ä°laÃ§larÄ± Nedir?</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> NasÄ±l Ã‡alÄ±ÅŸÄ±rlar?</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Piyasadaki GLP-1 Ä°laÃ§larÄ±</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Kilo KaybÄ±: Klinik Ã‡alÄ±ÅŸma Verileri</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Kilo KaybÄ±nÄ±n Ã–tesinde: SaÄŸlÄ±k FaydalarÄ±</li>
 </ul>
 </div>
 
 <!-- Visual Summary Slider (swipe on mobile) -->
 <div style="margin: 2rem 0; padding: 1.5rem; background: #f8fafc; border-radius: 16px;">
 <p style="font-weight: 600; color: #195157; margin-bottom: 1rem; font-size: 0.95rem;"> GÃ¶rsel Ã–zet:</p>
 <div style="display: flex; overflow-x: auto; scroll-snap-type: x mandatory; gap: 12px; border-radius: 12px; -webkit-overflow-scrolling: touch; scrollbar-width: none; -ms-overflow-style: none;">
 <style>.visual-slider::-webkit-scrollbar { display: none; }</style>
 <a href="../../images/social/glp1-tam-rehber-slide1.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-tam-rehber-slide1.jpg" alt="Kapak" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-tam-rehber-slide2.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-tam-rehber-slide2.jpg" alt="Ä°Ã§erik" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-tam-rehber-slide3.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-tam-rehber-slide3.jpg" alt="Ã–zet" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-tam-rehber-slide4.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-tam-rehber-slide4.jpg" alt="CTA" style="width: 100%; display: block;">
 </a>
 </div>
 <p style="text-align: center; margin-top: 0.75rem; font-size: 0.85rem; color: #6b7280;"> KaydÄ±rarak diÄŸerlerini gÃ¶rÃ¼n</p>
 </div>
 
 <div style="display: flex; flex-wrap: wrap; gap: 8px; padding-top: 1rem; border-top: 1px solid #e5e7eb;">
 <span style="font-size: 0.8rem; color: #9ca3af;">#uzunyasa</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#saÄŸlÄ±k</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#glp1</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#tam</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#rehber</span>
 </div>
 </div>
 <!-- END BLOG SUMMARY -->


<div class="cta-box">
 <h3>Size uygun tedavi seÃ§eneÄŸini Ã¶ÄŸrenin</h3>
 <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in testimizi tamamlayÄ±n</p>
 <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
 </div>

 <div class="author-box">
 <div class="author-avatar">UY</div>
 <div class="author-info">
 <h4>UzunYaÅŸa EditÃ¶ryal Ekibi</h4>
 <p>TÄ±bbi Ä°nceleme: Gastroenteroloji ve Endokrinoloji UzmanlarÄ± DanÄ±ÅŸma Kurulu</p>
 </div>
 </div>
 </div>
 </article>

 <footer><p style="font-size:0.85rem;font-style:italic;opacity:0.7;margin-bottom:0.5rem;">TÃ¼rkiye uzun yaÅŸasÄ±n diye.</p><p>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</p></footer>
<script src="../../scripts/animations.js"></script>
<script src="/scripts/premium-animations.js"></script>
</body>
</html>
